Zusammenfassung
Das Renin-Angiotensin-Aldosteron-System (RAAS) ist ein zentraler Steuerungsmechanismus, mit dem der Organismus seinen Elektrolythaushalt reguliert und einen ausreichenden Füllungszustand des Gefäßsystems sowie einen ausreichenden Blutdruck sicherstellt. Das RAAS ist in die Pathophysiologie verschiedener Erkrankungen wie der arteriellen Hypertonie, der chronischen Herzinsuffizienz oder der diabetischen Nephropathie involviert.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Weiterführende Literatur
Bader M (2010) Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 50: 439–465
Chatterjee S, Biondi-Zoccai G, Abbate A et al. (2013) Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 346: f55
Gradman AH, Kad R (2008) Renin inhibition in hypertension. J Am Coll Cardiol 51: 519–528
Lother A, Moser M, Bode C et al. (2015) Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol 55: 289–312
McMurray JJ (2010) Systolic heart failure. N Engl J Med 362: 228–238
McMurray JJ, Adamopoulos S, Anker SD et al. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869
McMurray JJ, Packer M, Desai AS et al. (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993–1004
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871–878
Swedberg K, Komajda M, Bohm M et al. (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet 376: 875–885
Tamargo J, Lopez-Sendon J (2011) Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov 10: 536–555
Zannad F, Mcmurray JJ, Krum H et al. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11–21
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Offermanns, S. (2016). Inhibitoren des Renin-Angiotensin-Aldosteron-Systems. In: Pharmakologie und Toxikologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46689-6_37
Download citation
DOI: https://doi.org/10.1007/978-3-662-46689-6_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46688-9
Online ISBN: 978-3-662-46689-6
eBook Packages: Medicine (German Language)